Zacks Small Cap Research – IRME: IR-Med’s positive safety and efficacy data from recent PressureSafe study supports price target of $3.00. – Technologist
By Thomas Kerr, CFA OTC:IRME READ THE FULL IRME RESEARCH REPORT New Clinical Efficacy Data for Detection of Pressure Injuries On February 20, 2024, the IR-Med (OTC:IRME) announced highly favorable proof of efficacy data for PressureSafe, its decision support device which uses infra-red spectroscopy combined with an AI-based algorithm for the early, non-invasive, and skin … Read more